Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1069-1074. doi: 10.19723/j.issn.1671-167X.2020.06.013

Previous Articles     Next Articles

Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports

Shi-bo LIU1,Hui GAO2,Yuan-chun FENG3,Jing LI4,Tong ZHANG5,Li WAN6,Yan-ying LIU7,Sheng-guang LI2,Cheng-hua LUO1,(),Xue-wu ZHANG7,()   

  1. 1. Department of Retroperitoneal Tumor Surgery
    2.Department of Rheumatology and Immunology
    3. Department of Radiology
    4. Department of Laboratory Medicine
    5. Department of Pathology
    6. Department of Nephrology, Peking University International Hospital, Beijing 102206, China
    7. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2020-07-31 Online:2020-12-18 Published:2020-12-13
  • Contact: Cheng-hua LUO,Xue-wu ZHANG E-mail:luochenghua@pkuih.edu.cn;xuewulore@163.com
  • Supported by:
    Peking University International Hospital Research Grant(YN2019QN02)

RICH HTML

  

Abstract:

Objective: To investigate the clinical features and outcome of hydronephrosis induced by retroperitoneal fibrosis (RPF), and to evaluate the effect of corticosteroid based therapy combined with surgical intervention of ureteral obstruction. Methods: A total of 17 RPF patients with hydronephrosis hospitalized in Peking University International Hospital from May 2016 to December 2019 were analyzed retrospectively. Results: The median age was 56 (53, 65) years, the male to female ratio was 2.4:1, and the disease duration was 4.00 (0.83, 8.00) months. The initial symptoms included back pain (9 cases), abdominal pain (6 cases), oliguria (2 cases) and lower limb edema (3 cases). Eight patients presented left hydronephrosis, 1 right hydronephrosis and 8 bilateral hydronephrosis. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were both elevated in 13 patients (76.5%, n=17). Immunoglobin (Ig) G4 increased in 5 cases (29.4%, n=17). IgG, IgE and IgA increased in 4 cases (30.8%, n=13), 4 cases (30.8%, n=13) and 1 case (7.7%, n=13), respectively. Among 12 patients who underwent biopsy, 3 patients were diagnosed with IgG4-relate disease. The level of IgG4 in the tissues varied, 6 cases expressed less than 10 per high power field (HPF) or no expression (50.0%). Only 2 cases expressed 10-30/HPF (16.7%), and 4 cases revealed more than 30/HPF (33.3%). Among the 17 patients with ureteral obstruction, no urinary drainage procedure was needed in 4 patients who had mild ureteral obstruction, whereas, ureteral stenting was carried out in the other 13 cases before drug treatment. Time was too short to evaluate the effect of urinary drainage procedures in 4 patients. For the rest, ureterolysis had to be performed in 3 cases after failed ureteral stent insertion. Successful drain removal was accomplished in all of these 9 patients and the mean time to drain removal was (6.7±3.0) months. In addition, 10 patients had complete medical records after an average follow-up time of 5 (3-13) months. Levels of ESR, CRP, IgG4, IgG, IgE, IgA were 54.0 (36.3, 98.5) mm/h, 26.8 (8.7, 53.0) mg/L, 1.34 (0.55, 3.36) g/L, 16.3 (13.0, 21.1) g/L, 40.5 (31.4, 203.0) IU/mL, 2.51 (1.82, 3.25) g/L at baseline, which all decreased predominantly after treatment. ESR, CRP, IgG4, IgG, IgE and IgA dropped by 38.5 (23.5, 54.3) mm/h (P<0.01), 23.0 (5.5, 52.0) mg/L (P<0.05), 0.92 (0.40, 2.85) g/L (P<0.01), 6.5 (1.7, 9.1) g/L (P<0.05), 23.7 (4.8, 162.0) IU/mL (P<0.05) and 0.77 (0.32, 1.26) g/L (P<0.05), respectively. Size of mass measured by CT/MRI imaging became smaller significantly and hydronephrosis relieved. Conclusion: Onset of RPF is insidious and lack of specific initial symptoms. Corticosteroid based therapy combined with surgical intervention of relieving obstruction is effective.

Key words: Retroperitoneal fibrosis, Hydronephrosis, Glucocorticoids, Surgical procedures, operative, Prognosis

CLC Number: 

  • R656.5

Table 1

Clinical features at presentation in 17 patients with RPF"

Clinical Features n (%)
Gender
Male 12 (70.6)
Female 5 (29.4)
Symptoms
Back pain 9 (52.9)
Abdominal pain 6 (35.3)
Oliguria 2 (11.8)
Lower limb edema 3 (17.6)
Diarrhea 1 (5.9)
Constipation 1 (5.9)
Laboratory studies
Increased CRP 13 (76.5)
Increased ESR 13 (76.5)
Increased IgG4 5 (29.4)
Increased IgG (n=13) 4 (30.8)
Increased IgM (n=13) 0
Increased IgE (n=13) 4 (30.8)
Increased IgA (n=13) 1 (7.7)
Decreased C3 (n=13) 1 (7.7)
Decreased C4 (n=13) 1 (7.7)
Hydronephrosis
Left hydronephrosis 8 (47.1)
Right hydronephrosis 1 (5.9)
Bilateral hydronephrosis 8 (47.1)
Radiographic class
Ⅰ+Ⅱ+Ⅲ 14 (82.4)
Ⅰ+Ⅱ+Ⅲ+Ⅳ 3 (17.6)
Pathological features (n=12)
<10 IgG4+ plasma cells/HPF 6 (50.0)
10-30 IgG4+ plasma cells/HPF 2 (16.7)
>30 IgG4+ plasma cells/HPF 4 (33.3)
IgG4+/IgG+ plasma cell ratio >40% 4 (33.3)
Storiform-type fibrosis 3 (25.0)
Obliterative phlebitis 4 (33.3)

Figure 1

The changes of ESR (A), CRP (B), IgG4 (C), IgG (D), IgE (E) and IgA (F) before and after treatment CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, immunoglobin."

Figure 2

The changes of axial diameter (A), transverse diameter (B) and anteroposterior diameter (C) in CT scan before and after treatment"

Figure 3

CT demonstrating retroperitoneal fibrosis (A) with resolution after treatment (B)"

[1] Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis[J]. Lancet, 2004,363(9419):1422-1426.
pmid: 15121404
[2] Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial[J]. Lancet, 2011,378(9788):338-346.
doi: 10.1016/S0140-6736(11)60934-3 pmid: 21733570
[3] Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation[J]. Medicine (Baltimore), 2009,88(4):202-207.
doi: 10.1097/MD.0b013e3181afc439
[4] Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012,25(9):1181-1192.
doi: 10.1038/modpathol.2012.72 pmid: 22596100
[5] Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process[J]. J Urol, 1948,59(6):1072-1079.
doi: 10.1016/s0022-5347(17)69482-5 pmid: 18858051
[6] Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: A clinicopathologic study with respect to immunoglobulin G4[J]. Am J Surg Pathol, 2009,33(12):1833-1839.
doi: 10.1097/pas.0b013e3181b72882 pmid: 19950407
[7] Rossi GM, Rocco R, Accorsi Buttini E, et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease[J]. Intern Emerg Med, 2017,12(3):287-299.
doi: 10.1007/s11739-016-1599-z pmid: 28070877
[8] Yamashita K, Haga H, Mikami Y, et al. Degree of IgG4+ plasma cell infiltration in retroperitoneal fibrosis with or without multifocal fibrosclerosis[J]. 2010,52(3):404-409.
[9] Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease[J]. Medicine (Baltimore), 2013,92(2):82-91.
doi: 10.1097/MD.0b013e318289610f
[10] Caiafa RO, Vinuesa AS, Izquierdo RS, et al. Retroperitoneal fibrosis: Role of imaging in diagnosis and follow-up[J]. Radiographics, 2013,33(2):535-552.
doi: 10.1148/rg.332125085 pmid: 23479712
[11] George V, Tammisetti VS, Surabhi VR, et al. Chronic fibrosing conditions in abdominal imaging[J]. Radiographics, 2013,33(4):1053-1080.
doi: 10.1148/rg.334125081 pmid: 23842972
[12] Pelkmans LG, Aarnoudse AJ, Hendriksz TR, et al. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis[J]. Nephrol Dial Transplant, 2012,27(7):2819-2825.
doi: 10.1093/ndt/gfr779 pmid: 22273666
[13] van Bommel EF, Siemes C, Hak LE, et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone[J]. Am J Kidney Dis, 2007,49(5):615-625.
doi: 10.1053/j.ajkd.2007.02.268 pmid: 17472843
[14] Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study[J]. Nephron Clin Pract, 2008,108(3):c213-220.
doi: 10.1159/000119715 pmid: 18332635
[15] Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis[J]. Ann Rheum Dis, 2013,72(9):1584-1586.
doi: 10.1136/annrheumdis-2013-203545 pmid: 23696631
[16] Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series[J]. Ann Intern Med, 2011,154(1):31-36.
doi: 10.7326/0003-4819-154-1-201101040-00005 pmid: 21200036
[17] Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis[J]. Ann Rheum Dis, 2012,71(2):311-312.
doi: 10.1136/annrheumdis-2011-200148 pmid: 21859695
[18] Li KP, Zhu J, Zhang JL, et al. Idiopathic retroperitoneal fibrosis (RPF): Clinical features of 61 cases and literature review[J]. Clin Rheumatol, 2011,30(5):601-605.
doi: 10.1007/s10067-010-1580-6 pmid: 20957401
[19] Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis[J]. J Am Soc Nephrol, 2016,27(7):1880-1889.
doi: 10.1681/ASN.2015101110 pmid: 26860343
[20] Mertens S, Zeegers AG, Wertheimer PA, et al. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction[J]. Int J Urol, 2014,21(3):283-288.
doi: 10.1111/iju.12234 pmid: 24033464
[21] Cristian S, Cristian M, Cristian P, et al. Management of idiopathic retroperitoneal fibrosis from the urologist's perspective[J]. Ther Adv Urol, 2015,7(2):85-99.
doi: 10.1177/1756287214565637 pmid: 25829952
[1] Jiale GAO, Zhongtao ZHANG. Current status and future perspectives of precision treatment for locally advanced rectal cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 247-250.
[2] Hao FU, Luyan SHEN, Bingyang HUANG, Shaohua MA. Clinical strategies for perioperative management of esophageal squamous cell carcinoma in the immunotherapy era [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 266-271.
[3] Bin LI, Han LIANG. Robotic gastrectomy: Research progress and practical challenges [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 416-422.
[4] Ebrahimi Farin, Zhiqiang FENG, Ebrahimi Faraz, Weihua HAN, Ziyang YU, Kuankuan JIA, Jingang AN. Surgical treatment outcomes of different stages of maxillary medication-related osteonecrosis of the jaw [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 107-114.
[5] Lingfu ZHANG, Ming CHEN, Xiaoyu ZHAO, Gang WANG, Long CUI, Xiaofeng LING, Lixin WANG, Zhi XU, Limei GUO, Chunsheng HOU. Gross classification of gallbladder cancer with primary lesion limited to the gallbladder wall and its correlation with prognosis and precancerous lesions [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 184-189.
[6] Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088.
[7] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[8] Zonghan LI, Yangyue HUANG, Ning LI, Minglei LI, Hongcheng SONG, Weiping ZHANG, Chao LIU. Preliminary application of domestic single-port serpentine arm robotic surgical system in children's pyeloplasty [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 662-665.
[9] Qiming ZHANG, Zebo CHEN, Yu TIAN, Dameng PAN, Lei LIU, Hongxian ZHANG, Lei ZHAO, Shudong ZHANG, Lulin MA, Xiaofei HOU. Experience summary of robot-assisted laparoscopic transplant nephrectomy [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 666-669.
[10] Xiaoteng YU, Yixuan HUANG, Xinfei LI, Changfu CHEN, Fangzhou ZHAO, Honggang YING, Zihao TAO, Yiming ZHANG, Liqing XU, Zhihua LI, Kunlin YANG, Liqun ZHOU, Xuesong LI, Zheng ZHAO. Surgical techniques and clinical outcomes of upper urinary tract reconstruction for stone-related ureteral strictures [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 670-675.
[11] Chao ZUO, Guoli WANG, Kunlin YANG, Xinyan CHE, Yisen MENG, Kai ZHANG. Comparison of efficacy and safety of transurethral thulium fiber laser enucleation of prostate in patients with different prostate volumes [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 711-716.
[12] Shihao LIU, Liqing XU, Xinfei LI, Kunlin YANG, Zhaoying LI, Zibo ZHANG, Xiang WANG, Wei-xiao FU, Zhihua LI, Xuesong LI. Evaluation of the feasibility and safety of a Chinese developed modular surgical robotic system for robot-assisted pyeloplasty [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 779-783.
[13] Huanrui WANG, Shicong LAI, Haopu HU, Zehua DING, Tao XU, Hao HU. Efficacy analysis of laparoscopy combined with flexible ureteroscope in the treatment of complex ureteral stricture [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 784-788.
[14] Shuai LIU, Zhuo LIU, Yunhe GUAN, Guoliang WANG, Xiaojun TIAN, Hongxian ZHANG, Lei LIU, Lulin MA, Shudong ZHANG. Robot-assisted laparoscopic inferior vena cava segmental resection for renal tumor with tumor thrombus invading the vascular wall [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 796-802.
[15] Zhao ZHAO, Weiyu ZHANG, Wenbo YANG, Yongjie ZHANG, Xiaopeng ZHANG, Huiying ZHAO, Gang ZHOU, Qiang WANG. Kidney transplantation in low-age, low-weight children: A report of two cases [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 803-807.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!